Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain: Boston Saturday, February 1, 2025, 14:00 Hrs [IST] Vertex Ph ...
The drug, Journavx by Vertex Pharmaceuticals ... also submitted data from a 250-person study that assessed the drug’s safety and tolerability in patients with pain from surgery, trauma or ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX ... for the treatment of adults with moderate-to-severe acute pain. The drug, which will be marketed under the brand name JOURNAVX, is the first ...
Vertex Pharmaceuticals (NASDAQ ... offering patients a strong safety profile. The U.S. Food and Drug Administration (FDA) approved the drug for use in acute pain, but Vertex aims to eventually ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...